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ABSTRACT
Colorectal carcinoma (CRC) is the third most common
cancer worldwide. Hereditary factors are important in
15%–35% of affected patients. This review provides an
update on the genetic basis of inherited predisposition
to CRC. Currently known genetic factors include a group
of highly penetrant mutant genes associated with rare
mendelian cancer syndromes and a group of common
low-penetrance alleles that have been identiﬁed through
genetic association studies. Additional mechanisms,
which may underlie a predisposition to CRC, will be
outlined, for example, variants in intermediate
penetrance alleles. Recent ﬁndings, including mutations
in POLE, POLD1 and NTHL1, will be highlighted, and we
identify gaps in present knowledge and consider how
these may be addressed through current and emerging
genomic approaches. It is expected that identiﬁcation of
the missing heritable component of CRC will be resolved
through evermore comprehensive cataloguing and
phenotypic annotation of CRC-associated variants
identiﬁed through sequencing approaches. This will have
important clinical implications, particularly in areas such
as risk stratiﬁcation, public health and CRC prevention.
BACKGROUND
Colorectal carcinoma (CRC) is the third most
common cancer worldwide, with approximately
1 360 600 new cases diagnosed in 2012.1 The
majority of CRCs occur sporadically, but in 15%–
35% of patients, hereditary factors are important
(reviewed in refs. 2 3). Here, we provide an update
on the genetic basis of inherited predisposition to
CRC. Currently known genetic factors include a
group of genes associated with rare mendelian
cancer syndromes, and a group of common low-
penetrance alleles that have been identiﬁed through
association studies in large cohorts of patients with
CRC and controls. We highlight recent ﬁndings
and identify gaps in present knowledge, and con-
sider how these may be addressed through genomic
approaches.
MENDELIAN COLORECTAL CANCER
SYNDROMES
Up to 5% of CRC occurs in the context of highly
penetrant dominantly inherited syndromes
(reviewed in ref. 2), and a much smaller proportion
occurs in recessive syndromes (see online supple-
mentary table S1). These syndromic disorders
include the adenomatous polyposes—familial aden-
omatous polyposis (FAP), MUTYH-associated
polyposis (MAP), NTHL1-associated polyposis,
polymerase proofreading-associated polyposis
and constitutional mismatch repair (MMR) deﬁ-
ciency syndrome; the hamartomatous polyposis
syndromes—juvenile polyposis syndrome, Peutz–
Jeghers syndrome and the PTEN hamartoma syn-
drome; hereditary mixed polyposis syndrome, in
which patients have multiple polyps of different
morphologies and Lynch syndrome (LS) when
colorectal cancer usually develops in the absence of
obvious polyposis (ﬁgures 1 and 2).
In these disorders, the risk of CRC in the
absence of preventive measures is very high (10%–
100%).4 The associated genes have been identiﬁed,
and testing for inherited mutations has become
routine in patients and families where these disor-
ders are suspected, including predictive testing in
asymptomatic family members to facilitate planning
of surveillance and preventive measures. Guidelines
are well established for the management of patients
with many of these diseases, for example, the
Mallorca Group guidelines for the management of
LS5 and FAP6 and the American College of
Gastroenterology guidelines for the management of
LS.7 However, there is still a paucity of large pro-
spective studies to inform robust estimates of
cancer risk and assess the efﬁcacy of surveillance
and interventions.
The recent identiﬁcation of colorectal adenoma
and carcinoma predisposing mutations in DNA
polymerase genes and in the base excision repair
gene NTHL1 serve as a reminder that there are still
likely to be gaps in our knowledge of rare high-
penetrance genes, which predispose to colorectal
cancer. Palles et al8 identiﬁed heterozygous germ-
line variants in POLE and POLD1 in individuals
with a family history of multiple adenomas and
CRC, but no detectable mutations in known
polyposis-associated genes, including APC or
MUTYH. The study employed whole-genome
sequencing, linkage and association approaches.
Two high-penetrance variants, POLE p.Leu424Val
and POLD1 p.Ser478Asn, were localised to the
proofreading (exonuclease) domains of these poly-
merases. POLE p.Leu424Val was subsequently also
identiﬁed in 12 unrelated cases in a cohort of 3805
European individuals with colorectal cancer
enriched for a family history of CRC, early onset
disease and multiple adenomas. Ten individuals
from two families were found to have the POLD1
p.Ser478Asn variant with a further individual iden-
tiﬁed in the validation phase.8 Tumours in these
patients were microsatellite stable, but acquired
base substitution mutations. More recently, the two
germline mutations were studied in a further
cohort of patients with unexplained familial and
early onset CRC and/or polyposis. Valle et al9
investigated 858 such patients: POLE p.Leu424Val
was identiﬁed as a de novo mutation in a patient
with sporadic polyposis and CRC. While POLD1
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p.Ser478Asn was not observed, the group found a novel muta-
tion, POLD1 c.1421T>C (p.Leu474Pro), in a family fulﬁlling
the Amsterdam II criteria (that are used to identify families who
may have LS), but whose members had MMR-proﬁcient
tumours. A similar study was carried out by Elsayed et al.10
They examined 1188 patients with familial CRC and polyposis
for the two common mutations, and identiﬁed three patients
(0.25%) with the POLE p.Leu424Val variant.10 The tumours
Figure 1 H&E microscopic images of
colorectal polyps. (A) Tubular adenoma
with low-grade dysplasia. (B)
Hyperplastic polyp: note the presence
of glands in the centre of the image
with a serrated/‘tooth-like’ appearance.
(C) A Peutz–Jeghers polyp. The glands
are separated by bundles of smooth
muscle. (D) A juvenile polyp. Cystically
dilated glands are present in an
oedematous and inﬂamed stroma.
Figure 2 Diagram illustrating relationships between genes and signalling pathways involved in inherited colorectal cancer syndromes. FAP, familial
adenomatous polyposis syndrome; HMPS, hereditary mixed polyposis syndrome; JPS, juvenile polyposis syndrome; LS, Lynch syndrome; MAP,
MUTYH-associated polyposis; NTHL1, NTHL1-associated polyposis; PJS, Peutz–Jeghers syndrome; PPAP, polymerase proofreading-associated
polyposis syndrome.
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from these patients were microsatellite unstable, and immuno-
histochemistry showed MSH6/MSH2 deﬁciency, although there
were no germline mutations in the corresponding genes.10 Spier
et al11 carried out targeted sequencing of POLD1, POLD2,
POLD3, POLE, POLE2, POLE3 and POLE4 in 266 unrelated
patients who had polyposis or who fulﬁlled Amsterdam criteria,
but in whom no germline mutation had been identiﬁed in LS or
other polyposis syndrome-associated genes. POLE p.Leu424Val
was detected in four patients, and the group identiﬁed a further
nine potentially pathogenic POL variants. Bellido et al12 studied
the exonuclease domains of POLE and POLD1 in 441 patients
with familial non-polyposis colorectal cancer and 88 patients
with polyposis. They used massively parallel sequencing to iden-
tify seven novel or rare genetic variants.12
Very recently, Weren et al13 applied whole exome sequencing
in 51 patients with multiple colorectal adenomas who did not
have identiﬁed mutations in APC or MUTYH. They found that
seven members of three families had homozygous germline
mutations in NTHL1. Tumours from affected individuals
showed a signiﬁcant increase in the proportion of C:G>T:A
transitions, consistent with the predicted effects of homozygous
loss-of-function mutations in NTHL1 on the accumulation of
somatic mutations. Further studies of larger patient cohorts are
required to characterise the newly recognised disorder
NTHL1-associated polyposis.
While mutations in genes that are already known to be asso-
ciated with polyposis syndromes can be identiﬁed in the major-
ity of patients with many tens or hundreds of polyps, the extent
to which unidentiﬁed changes in these genes account for the
remainder is unclear. Alternatively, further currently unknown
genes or other aetiological factors may be involved in some
cases. Genes encoding components of pathways already impli-
cated in CRC predisposition that regulate Wnt or BMP/TGF-B
signalling, cell adhesion, ubiquitin-mediated proteolysis and
DNA repair are further plausible functional candidates, as are
genes which have a role in other cancer predisposition syn-
dromes. Yurgelun et al14 have demonstrated that in a large
cohort of patients with early onset colorectal cancer, 1.3% (6/
457) had germline mutations in TP53, none of whom met the
clinical criteria for Li–Fraumeni syndrome. This frequency is
comparable with the prevalence of germline APC mutations in
colorectal cancer.14
UNUSUAL MUTATIONAL MECHANISMS IN MENDELIAN
COLORECTAL CANCER SYNDROMES
Historical approaches that were employed for molecular genetic
diagnosis such as Sanger sequencing and multiplex ligation-
dependent probe ampliﬁcation have incomplete sensitivity for
the detection of mutations in coding sequences, and diagnostic
laboratories rarely test for point mutations in non-coding
sequences, except at intron–exon boundaries. In one study of
171 patients with multiple colorectal adenomas in whom APC
or MUTYH mutations had not been detected by Sanger sequen-
cing, the APC coding region was retested using high resolution
melt analysis leading to the detection of pathogenic heterozy-
gous APC mutations in 10 (6%) and mosaic APC mutations in
two (1%).15 Others have searched for and identiﬁed promoter
mutations, deep intronic mutations, complex genomic rearran-
gements and mosaic mutations in a proportion of polyposis
cases originally thought not to harbour mutations in APC or
MUTYH.16–21 The application of next-generation sequencing to
rapidly screen whole genomic loci at great depth overcomes
many of the limitations of other laboratory techniques, but
interpretation and functional characterisation of non-coding var-
iants remains problematic.
Constitutional epimutation, the epigenetic silencing of an
allele in normal somatic tissues, has been demonstrated to affect
MLH1 or MSH2 in a number of patients with LS, mostly spor-
adic cases, with MMR-deﬁcient tumours.22–25 A variety of
sequence changes outside of the coding regions of the genes
themselves has been shown to lead to promoter methylation
and allele silencing. These include promoter mutations26 and a
relatively frequent deletion in the 30 end of the EPCAM gene
that lies adjacent to MSH2. This leads to transcriptional read-
through from EPCAM into MSH2 and MSH2 promoter methy-
lation in the epithelial tissues in which EPCAM is expressed.27
(Constitutional epimutation has not been reported in other
CRC syndromes).
Mosaicism, the presence of genetically distinct cell lines in the
same individual, poses a particular challenge for mutation detec-
tion. Somatic mosaicism for APC mutations in which mutant
alleles are present at lower frequency than expected in heterozy-
gotes (ie, <50% and often much lower) appears to be relatively
common among patients with sporadic FAP.17 Segmental
somatic mosaicism in which the mutation is conﬁned to speciﬁc
body segments requires analysis of tissue from the affected area,
and has been reported in patients with FAP who have had APC
mutations identiﬁed in the affected part of the colon, but
undetectable in other somatic tissues.28–30 The massively paral-
lel nature of next-generation sequencing makes this approach
very suitable for the detection of mutant alleles present at low
frequency,31 but does not overcome problems of segmental
mosaicism.
SERRATED POLYPOSIS SYNDROME
The aetiological basis of serrated polyposis syndrome (SPS) is
currently unknown. Most hyperplastic, metaplastic or serrated
polyps are small (<1 cm) sporadic lesions, but patients with SPS
develop multiple polyps that may be large (>1 cm). The condi-
tion was ﬁrst described in 1980 by Williams et al.32 They
observed seven patients, with a mean age of 37.4 years, who
each had at least 50 colorectal polyps (then termed ‘metaplastic
polyps’). At that time, the authors concluded that ‘it is impos-
sible to deduce whether or not “metaplastic polyposis” is a dis-
tinct entity. There is no good evidence that it is familial in this
small series, but the appearance of numerous metaplastic polyps
of an unusually large size and conﬁguration, predominantly in
young males, might suggest a speciﬁc disease’. The identiﬁcation
of further similar patients led Burt and Jass to propose a deﬁn-
ition for ‘hyperplastic polyposis syndrome’ in the 2000 WHO
classiﬁcation of tumours.33 This deﬁnition was modiﬁed in
2010, and the disease was renamed serrated polyposis syn-
drome.34 Current diagnostic criteria for SPS require a patient to
have:
1. at least ﬁve serrated (hyperplastic) polyps proximal to the
sigmoid colon, two of which are >10 mm in diameter or;
2. any number of serrated polyps proximal to the sigmoid
colon in an individual who has a ﬁrst-degree relative with
serrated polyposis or;
3. more than 20 serrated polyps of any size distributed
throughout the colon.
It was thought that SPS affected 1 in 3000 individuals
between the ages of 55 and 64 years (reviewed in ref. 35) and as
many as 1 in 151 patients having a colonoscopy following a
positive faecal occult blood test (reviewed in ref. 36). SPS shows
no sex predilection, and the mean age of diagnosis is 55
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years.37 38 In addition to hyperplastic lesions, there are often
conventional adenomas present in the bowel.36
Patients with SPS seem to fall into one of two ‘molecular
groups’ (reviewed in refs. 37 38), one with relatively few large
right-sided polyps, which harbour BRAF mutations, the other
with many small left-sided lesions, which often harbour KRAS
mutations (reviewed in refs. 37 38). The combined incidence of
KRAS and BRAF mutations ranges from 64% to 75% (reviewed
in refs. 37 39). Polyps with epithelial dysplasia have higher rates
of these mutations (90%) (reviewed in ref. 37). Some patients
may have a combination of left-sided and right-sided lesions.38
Patients with SPS are at an increased risk of developing CRC,
which typically occurs between 50 and 60 years of age
(reviewed in ref. 34). Malignancy is associated with a larger
number of polyps, the presence of dysplasia (reviewed in refs.
37 40), and the existence of conventional adenomas in addition
to hyperplastic polyps.35 The estimated incidence of CRC in
patients with SPS varies from 14% to 58% (reviewed in refs.
35 40–42). Interestingly, a large proportion of CRCs seen in
patients with SPS do not develop through the ‘serrated pathway
of carcinogenesis’, driven by BRAF mutation.35 The cancers
show various molecular changes, including those more likely to
be associated with the traditional adenoma–carcinoma pathway,
for example, β-catenin activation and/or overexpression of
p53.35
SPS may be a genetic disease, but if so, the mode of inherit-
ance is unclear and recessive and dominant models have both
been suggested (reviewed in ref. 37). SPS could be the result of
a predisposition to promoter hypermethylation (reviewed in
refs. 37 43), and some studies have reported hypermethylation
in apparently normal colonic mucosa in patients with SPS
(reviewed in ref. 44).
LOW-PENETRANCE ALLELES AND POLYGENIC
PREDISPOSITION
Genome-wide association studies (GWAS) have so far identiﬁed
approximately 40 CRC susceptibility loci, each of which is asso-
ciated with a small increase in CRC risk (see online supplemen-
tary table S2). Variants at these loci are not strictly ‘mutations’,
and may alter gene expression or function or, more usually, be
in linkage disequilibrium with the mechanistic variant. On the
basis of an additive model, the 10 CRC loci initially identiﬁed
were thought to collectively account for approximately 6% of
excess familial risk.45 However, it is clear that such an additive
model cannot adequately explain increases in disease risk,46 and
it appears that the combined effect of such variants follows a
multiplicative (log additive) risk model (reviewed in ref. 47).
The risks associated with each of the variants have been much
too small for translation to testing in clinical practice, but the
development of algorithms estimating cumulative risks asso-
ciated with carriage of multiple alleles are expected to lead to
clinical application, as has already been proposed in the context
of breast cancer.48 Dunlop et al49 sought to assess the feasibility
of CRC risk prediction using common genetic variant data com-
bined with other risk factors. They used binary logistic regres-
sion to assess the combined effects of age, gender, family history
and genotypes at 10 susceptibility loci that confer only small
CRC risks. They found that while genotype data provided add-
itional information that complemented age, gender and family
history as risk factors, clinically useful individualised genetic risk
prediction was not currently feasible. However, it was proposed
that such risk prediction models might help to identify high-risk
groups that could beneﬁt from public health measures to
prevent CRC.
INTERMEDIATE PENETRANCE ALLELES
While 15%–35% of colorectal cancers are believed to occur in
the context of signiﬁcant inherited predisposition (reviewed in
ref. 2 3), currently identiﬁed genetic factors can probably only
account for up to 10% of CRCs. One type of currently missing
heritability is likely to be mutations (variants) of intermediate
penetrance, that is, those which confer a relative cancer risk
from 1.5 to 5.50 In general, the allele frequencies of such muta-
tions will be too low to have been identiﬁed in GWAS and pene-
trance too low to have been identiﬁed in traditional family
linkage studies. However, as sequencing-based approaches have
been applied, such mutations have already been identiﬁed in
patients and families with breast cancer, in genes such as
CHEK2, ATM, PALB2 and BRIPI,50 and it is anticipated that
sequencing approaches in patients and families with CRC will
identify comparable mutations that predispose to CRC. For
example, a very recent report suggests that mutations in the
DNA repair gene FAN1 may predispose to colorectal cancer.51
CONCLUSION
CRC is the third most common cancer worldwide,1 and inher-
ited factors are important in a signiﬁcant proportion of cases.
Previous genetic and genomic studies have identiﬁed the basis of
only a small part of this heritability. Clinical application of
testing for highly penetrant and therefore high-risk mutations
has become an established part of managing CRC, and is
enshrined in international guidelines.5–7 By contrast, the incom-
plete picture of the genomic architecture of inherited predispos-
ition to CRC has so far precluded the clinical application of
testing for low-penetrance variants. It is expected that identiﬁca-
tion of the missing heritable component of CRC will be
resolved through evermore comprehensive cataloguing and
phenotypic annotation of CRC-associated variants identiﬁed
through sequencing approaches. Clinical applications in public
health and CRC prevention may follow.
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